July 19, 2018 / 6:28 AM / Updated an hour ago
Novartis to pay 95 million euros to Galapagos, MorphoSys for skin drug
ZURICH (Reuters) - Novartis said on Thursday it will pay 95 million euros ($110.49 million) to Galapagos and MorphoSys to license a prospective medicine targeting the skin condition atopic dermatitis, as the Swiss drugmaker strengthens its foothold in immunology.
FILE PHOTO: Swiss drugmaker Novartis' logo is seen at the company's plant in the northern Swiss town of Stein, Switzerland October 23, 2017. REUTERS/Arnd Wiegmann/File Photo
Novartis, which said the deal includes additional payments, royalties and fees pending the achievement of milestones, already has a blockbuster drug, Cosentyx, in immunology with accelerating sales in psoriasis and ankylosing spondolitis.
Reporting by John Miller; Editing by Jan Harvey
Our Standards:The Thomson Reuters Trust Principles.
0 : 0
- narrow-browser-and-phone
- medium-browser-and-portrait-tablet
- landscape-tablet
- medium-wide-browser
- wide-browser-and-larger
- medium-browser-and-landscape-tablet
- medium-wide-browser-and-larger
- above-phone
- portrait-tablet-and-above
- above-portrait-tablet
- landscape-tablet-and-above
- landscape-tablet-and-medium-wide-browser
- portrait-tablet-and-below
- landscape-tablet-and-below